Wyss InstituteMedicine – Wyss Institute

Decoding inflammatory bowel disease – on a chip

Jessica Leff — Thu, 21 May 2026 09:30:43 +0000

By Benjamin Boettner (BOSTON) — Inflammatory bowel disease (IBD), which comprises the inflammatory conditions Crohn’s disease and ulcerative colitis, affects about 1.6 million Americans, many of whom cannot be effectively treated. This is mostly due to a lack of understanding of what exactly causes the increased inflammation, fibrosis, and compromised intestinal barrier that underlie this…

Source

Multidisciplinary Wyss team receives 2026 Lush Prize Science Award

Jessica Leff — Mon, 18 May 2026 18:30:48 +0000

(BOSTON) — The Wyss Institute for Biologically Inspired Engineering at Harvard University is proud to announce that the Biosensing, Microfluidics, and Microsystems team, led by Wyss Senior Engineer Adama Sesay, Ph.D., together with the Female Reproductive Health team, has received the 2026 Lush Science Prize. The prize recognizes their work developing next-generation, sensor-integrated human Organ…

Source

Materializing safe, on-demand living therapeutics

Jessica Leff — Thu, 14 May 2026 17:55:55 +0000

By Benjamin Boettner (BOSTON) — Patient recovery from many debilitating conditions and diseases could be sped up significantly and be more effective if drugs and therapeutic molecules were delivered right to where they are needed in the body, over the entire regenerative process, and in doses finely tuned to therapeutic needs. An intriguing way to achieve this is the use of implantable…

Source

Ultrasensitive test detects biomarkers for specific form of dementia

Mariel Schoen — Tue, 05 May 2026 13:55:08 +0000

By MGB Communications (BOSTON) — Dementia affects over 57 million people worldwide, a number expected to nearly double in the next 20 years. This permanent loss of cognitive abilities affects daily function and can be caused by multiple brain pathologies, including well known ones like Alzheimer’s disease (AD). Right now, biomarkers permit diagnosis of AD but not rarer pathologies like…

Source

Wyss Institute technologies enable breakthrough in astronaut health research aboard NASA’s Artemis II mission

Jessica Leff — Thu, 09 Apr 2026 14:55:20 +0000

By Alexandra Jirstrand (BOSTON) – Launched on April 1, 2026, Artemis II is a historic, approximately 10-day lunar flyby mission that is sending four astronauts farther into space than any humans have traveled since the Apollo era, marking a critical step toward sustained lunar exploration and future missions to Mars. The Wyss Institute for Biologically Inspired Engineering at Harvard…

Source

Nucleic Acid Delivery Consortium

Mariel Schoen — Fri, 13 Mar 2026 15:13:09 +0000

Nucleic acid therapies are emerging as a revolutionary class of medicines. Using engineered DNA or RNA molecules, they treat diseases at their genetic source, thus offering potential cures for a large variety of disorders, ranging from genetic disorders to cancers and infectious diseases. Different technologies, including mRNA, short interfering RNAs (siRNA), antisense oligonucleotides (ASOs)…

Source

Toward engineering a human kidney collecting duct system

Jessica Leff — Fri, 30 Jan 2026 14:50:56 +0000

By Benjamin Boettner (BOSTON) — The human kidney filters about a cup of blood every minute, removing waste, excess fluid, and toxins from it, while also regulating blood pressure, balancing important electrolytes, activating Vitamin D, and helping the body produce red blood cells. This broad range of functions is achieved in part via the kidney’s complex organization. In its outer region…

Source

Wyss Institute-led collaboration awarded by ARPA-H PRINT program to engineer off-the-shelf, universal, transplant-ready graft for liver failure

Jessica Leff — Fri, 16 Jan 2026 14:55:47 +0000

By Benjamin Boettner (BOSTON) — The majority of human illnesses are caused by damage to a single organ, like the liver, whose failure accounts for 2M deaths worldwide every year. Orthotopic transplants are the only curative therapy available, but the severe shortage of donor organs, which are reserved for the most severe cases, leaves millions of patients without an accessible solution.

Source

A CRISPR fingerprint of pathogenic C. auris fungi

Jessica Leff — Wed, 14 Jan 2026 13:45:36 +0000

By Benjamin Boettner (BOSTON) — Infection with the pathogenic yeast fungus Candida auris (C. auris) can wreak havoc on the health of hospital patients and residents of nursing homes, especially those who are already weakened by other illnesses. The pathogen easily spreads and colonizes surfaces and objects where it can survive for weeks to months, and is often resistant to standard…

Source

First-in-human clinical trial of personalized, biomaterial-based cancer vaccine demonstrates feasibility, safety, and immune activation

Jessica Leff — Wed, 10 Dec 2025 17:11:46 +0000

By Benjamin Boettner (BOSTON) — The first-in-human phase I clinical trial assessing the feasibility and safety of WDVAX, an immunostimulatory biomaterial-based cancer vaccine, in a cohort of 21 patients with stage 4 metastatic melanoma, was concluded with positive outcomes that encourage future vaccine developments and trials to test them in combination with immune checkpoint inhibitor…

Source